Development Derivative Liability - Narrative (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2020 USD ($)	Jun. 30, 2022 USD ($) payment tranche $ / shares shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) payment tranche $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Derivative [Line Items]
Common stock, shares issued (in shares) | shares		49,888,083		49,888,083		48,220,557
Common stock, shares issued, value		$ 50,000		$ 50,000		$ 48,000
Gain/(loss) from remeasurement of development derivative liability		8,719,000	$ (5,777,000)	15,952,000	$ (7,203,000)
SFJ Pharmaceuticals X, Ltd.
Derivative [Line Items]
Proceeds from partnership contribution				21,000,000
Derivative
Derivative [Line Items]
Initial liability				2,100,000
Funding during the period				7,700,000	30,400,000
Gain/(loss) from remeasurement of development derivative liability		$ 8,700,000	$ (5,800,000)	16,000,000	$ (7,200,000)
SFJ Agreement
Derivative [Line Items]
Potential milestones payment				$ 120,000,000
Cost of borrowing rate				16.00%
SFJ Pharmaceuticals
Derivative [Line Items]
Cost of borrowing rate				2.50%
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | SFJ Agreement
Derivative [Line Items]
Common stock, shares issued (in shares) | shares		2,200,000		2,200,000
Shares issued (in usd per share) | $ / shares		$ 6.50		$ 6.50
Common stock, shares issued term				10 years
Number of tranches | tranche		2		2
Common stock, shares issued, value		$ 7,900,000		$ 7,900,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | SFJ Agreement | Derivative
Derivative [Line Items]
Funding during the period				$ 7,682,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | SFJ Agreement | Tranche A
Derivative [Line Items]
Common stock, shares issued (in shares) | shares		1,100,000		1,100,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | SFJ Agreement | Tranche B
Derivative [Line Items]
Common stock, shares issued (in shares) | shares		1,100,000		1,100,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | bentracimab | SFJ Agreement
Derivative [Line Items]
Potential milestones payment receivable	$ 120,000,000			$ 30,000,000
Initial payment for license				90,000,000
Additional payment for license				99,000,000
Initial payment received for license agreement				10,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | bentracimab | United States Food And Drug Administration | SFJ Agreement
Derivative [Line Items]
Initial payment for license				5,000,000
Additional payment for license				$ 325,000,000
Number of additional annual payments | payment		7		7
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | bentracimab | European Medicines Agency | SFJ Agreement
Derivative [Line Items]
Initial payment for license				$ 5,000,000
Additional payment for license				$ 205,000,000
Number of additional annual payments | payment		7		7
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | bentracimab | Pharmaceuticals And Medical Devices Agency Of Japan And National Medical Productions Administration Of China | SFJ Agreement
Derivative [Line Items]
Initial payment for license				$ 1,000,000
Additional payment for license				$ 59,000,000
Number of additional annual payments | payment		8		8